Lubiprostone (Amitiza)
Other Medications · Approved since 2006
Description
Lubiprostone is a chloride channel activator approved by the FDA for treating chronic constipation and constipation-predominant irritable bowel syndrome. In colorectal cancer care, lubiprostone serves as supportive therapy to manage treatment-related constipation and may be used as part of bowel preparation protocols for colonoscopy procedures. Recent clinical research has explored its potential role in combination with maintenance therapy for preventing postoperative recurrence in patients with peritoneal metastatic coloreceal cancer.
Mechanism of Action
Lubiprostone activates ClC-2 chloride channels in the gastrointestinal tract, leading to increased fluid secretion into the intestinal lumen. This mechanism promotes intestinal motility and alleviates constipation by increasing the water content of stool and facilitating easier passage through the colon.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Amitiza |
| Category | Other Medications |
 Status | FDA Approved |
| Administration | Oral |
| Year Approved | 2006 |
| Clinical Trials | 2 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.